Danish pharmaceutical company novo-nordisk a/s announced an investment of 0.1582 billion US dollars to upgrade its insulin production facility in Montes Claros, Minas Gerais, southeastern Brazil, marking a significant expansion of the company's manufacturing capacity. According to a statement released by the company on Friday, these funds will be used to renovate existing infrastructure and implement sustainable development projects within the factory. This investment is equivalent to 0.864 billion Brazilian reais, at the current exchange rate of 1 US dollar to 5.4627 Brazilian reais. This development signifies a significant progress in the company's business in Brazil, strengthening its position in the Latin American market and its global production network.